Moxifloxacin

Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].

Product Specifications

CAS Number

[151096-09-2]

Product Name Alternative

BAY 12-8039 (free base)

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/moxifloxacin.html

Purity

99.72

Solubility

DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3OC)C1=O)O

Molecular Formula

C21H24FN3O4

Molecular Weight

401.43

Precautions

H302, H315, H320, H335

References & Citations

[1]Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58 (5) : p. 379-88.|[2]Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59 (1) :115-39.|[3]Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52 (5) :1697-702.|[4]Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58 (2) :96-102.